Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY)

77 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q2 2025.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 115,567,681 shares of 1,571,428,571 outstanding shares and own 7.4% of the company stock.
Largest 10 shareholders include EcoR1 Capital, LLC (27,404,070 shares), Long Focus Capital Management, LLC (23,756,687 shares), Two Seas Capital LP (22,580,701 shares), NEA Management Company, LLC (17,079,778 shares), MPM ASSET MANAGEMENT LLC (4,809,677 shares), MPM BIOIMPACT LLC (4,411,821 shares), MORGAN STANLEY (4,232,268 shares), Rock Springs Capital Management LP (2,483,468 shares), ACADIAN ASSET MANAGEMENT LLC (1,964,141 shares), and RENAISSANCE TECHNOLOGIES LLC (1,882,860 shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.